“Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: ​ Data From 11 Trials With Over 3000 Patient-Years of Exposure”. SKIN The Journal of Cutaneous Medicine 9, no. 1 (January 13, 2025): s511. Accessed April 13, 2025. https://skin.dermsquared.com/skin/article/view/3152.